Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 239 clinical trials
Featured trial
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

to vehicle cream will be rerandomized (1:1) in a blinded manner to 1 of the 2 active treatment groups (ruxolitinib cream 0.75% or 1.5%).

  • 0 views
  • 11 May, 2022
  • 20 locations
Featured trial
A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial

A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial

  • 2258 views
  • 23 Nov, 2020
  • 22 locations
Featured trial
A multi-center, double-blind, randomized, vehicle-controlled, parallel-group study to compare Perrigo UK FINCO ingenol mebutate topic Gel 0.015% to Leo Pharma Inc. Picato Topical Gel 0.015% (Ingenol Mebutate Topical Gel 0.015%), and both active treatments to a vehicle control in the treatment of actinic keratosis on the head region (face or scalp)

A multi-center, double-blind, randomized, vehicle-controlled, parallel-group study to compare Perrigo UK FINCO ingenol mebutate topic Gel 0.015% to Leo Pharma Inc. Picato Topical Gel 0.015% (Ingenol Mebutate Topical Gel 0.015%), and both active treatments to a vehicle control in the treatment of actinic keratosis on the head region (face or …

  • 104 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A double-blind, randomized, parallel-group vehicle-controlled, multi-center study comparing a generic tazarotene cream, 0.05% to reference listed drug tazorac (tazarotene) cream, 0.05% and both active treatments to a vehicle control in the treatment of plaque psoriasis

A double-blind, randomized, parallel-group vehicle-controlled, multi-center study comparing a generic tazarotene cream, 0.05% to reference listed drug tazorac (tazarotene) cream, 0.05% and both active treatments to a vehicle control in the treatment of plaque psoriasis

  • 186 views
  • 08 Nov, 2020
  • 1 location
Featured trial
Modified Comprehensive Behavioral Intervention for Tics for Children with Tic Disorder, Co-occurring Attention Deficit Hyperactivity Disorder, and Psychosocial Impairment

Modified Comprehensive Behavioral Intervention for Tics for Children with Tic Disorder, Co-occurring Attention Deficit Hyperactivity Disorder, and Psychosocial Impairment

  • 105 views
  • 25 Mar, 2021
  • 1 location
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE (RECAST SLE)

participants. The study duration will be 48 weeks, with a safety follow-up through week 56.There will be 3 parallel arms - 2 active treatment and 1 placebo.

  • 0 views
  • 18 Apr, 2022
  • 70 locations
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

-blind period (a participant receives either active Dose A, Dose B or Placebo), a 39-week OLE Treatment Period (all participants receive active treatment) and a 2-week Follow-Up Period

endoscopy
  • 0 views
  • 27 Apr, 2022
  • 6 locations
(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if

  • 14 views
  • 17 May, 2022
  • 106 locations
Eptinezumab in Participants With Episodic Cluster Headache (ALLEVIATE)

The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)

  • 1 views
  • 15 May, 2022
  • 74 locations
A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

The purpose of this study is to determine whether intravenous temanogrel is a safe and effective treatment for microvascular obstruction (MVO) in adult participants undergoing percutaneous coronary intervention (PCI).

  • 0 views
  • 10 May, 2022
  • 12 locations